

IF: 1.59

ISSN 2221-1691(Print)
ISSN 2588-9222(Online)
CODEN APJTC7

Asian Pacific Journal of Tropical Biomedicine



10

2019



Vol 9 No 10 Oct



Original Article

Asian Pacific Journal of Tropical Biomedicine

journal homepage: www.apjtb.org



doi: 10.4103/2221-1691.269525

Impact factor: 1.59

Bioguided isolation of antimicrobial polyphenols from *Cuspidaria convoluta* leaves and their synergistic effect with antibioticsCarola A. Torres^{1,2✉}, Mario A. Sturla³, Ana M. Romero⁴, María A. Judis⁴¹Department of Basic and Applied Sciences, Microbiology Laboratory, Universidad Nacional del Chaco Austral, Comandante Fernández 755, Presidencia Roque Sáenz Peña, Chaco, Argentina²Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina³Department of Basic and Applied Sciences, Laboratory of Organic Chemistry, Universidad Nacional del Chaco Austral, Argentina⁴Department of Basic and Applied Sciences, Food Industry Laboratory, Universidad Nacional del Chaco Austral, Argentina

ARTICLE INFO

Article history:

Received 7 April 2019

Revision 10 May 2019

Accepted 17 September 2019

Available online 24 October 2019

Keywords:

Luteolin

Ampicillin

MIC reduction

Antimicrobial agents

ABSTRACT

Objective: To identify and isolate phenolic compounds from *Cuspidaria convoluta*, and to evaluate their antibacterial activity and synergistic effect with antibiotics.**Methods:** The crude extract was prepared by maceration with methanol (5%). The dry extract was suspended in water and fractionated successively. The most active extract was selected by its antibacterial activity and its total phenol content was determined by spectrophotometry and by HPLC-MS/MS. Bioactive fractions of the most active extract were separated by column chromatography and evaluated by bioautography. Isolated compounds were identified. Minimum inhibitory concentration (MIC) of these compounds was determined by microdilution broth method, and synergism with antibiotics (ampicillin, gentamicin and oxacillin) was tested by checkerboard and time-kill assays.**Results:** Coumaric acid, catechin/epicatechin, and luteolin were purified and identified from the extract. There was an increase in the antibacterial activity of antibiotics when they were combined with these compounds. The combination of luteolin and ampicillin had the most potent antibacterial activities. The MICs of oxacillin for each of methicillin-resistant *Staphylococcus aureus* strains were reduced between 4 and 8-fold when these strains were coincubated with sub-MIC ($\leq \frac{1}{2}$ MIC) levels of these compounds, demonstrating that the combination had synergistic effect for all cases.**Conclusions:** *Cuspidaria convoluta* contains important pharmacologically active substances that can be used to improve antibiotic efficacy.

1. Introduction

Phenolic compounds are secondary plant metabolites that constitute one of the most common and widespread groups of substances in plants. They are responsible for pigmentation, growth,

reproduction, and resistance to pathogens. The antibiotic properties of phenolic compounds are one of the primary defense mechanisms of plants. Most bioactive plant-based antimicrobials are phenol derivatives, controlling bacterial growth by altering their membrane

✉Corresponding author: Carola A. Torres, Comandante Fernández 755, Presidencia Roque Sáenz Peña, Chaco, Argentina.

Tel: +54 364 4420137

E-mail: carito@uncaus.edu.ar

Funding: This work is financially supported by Secretaría de Ciencia y Técnica UNCAUS and by Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

©2019 Asian Pacific Journal of Tropical Biomedicine Produced by Wolters Kluwer-Medknow. All rights reserved.

How to cite this article: Torres CA, Sturla MA, Romero AM, Judis MA. Bioguided isolation of antimicrobial polyphenols from *Cuspidaria convoluta* leaves and their synergistic effect with antibiotics. Asian Pac J Trop Biomed 2019; 9(10): 434-442.

permeability or reducing the pH. However, their activity is generally weak and is often non-specific.

The combination of natural drugs to treat complex infectious diseases is an approach to suppress bacterial resistance that is expected to usually develop when a single drug is used[1]. This strategy is designed to combine antimicrobial compounds with different mechanisms of action for multiple targets. It could produce a synergistic antibacterial activity. This approach includes combinations of extracts with antimicrobial properties, combinations between individual natural products and combinations of extracts with antibiotics[2,3]. Over the last decade, the search for synergistic interaction between plant extracts and commercial antibiotics that have already generated resistance in bacteria has increased significantly. Examples include the combination of β -lactams with α -mangostin isolated from mangosteen fruit[4] or with quercetin or kaempferol from various fruits, vegetables, and grains[5], which substantially increased the efficacy of the therapy in β -lactam resistant bacterial strains. Plant extract/antibiotic combinations not only contribute to and enhance the overall antimicrobial effect, but can also act as resistance modifying/modulating agents. For example, several extracts and essential oils of *Salvia* spp. and *Matricaria recutita* have been reported to have synergistic effects with oxacillin on methicillin resistant *Staphylococcus epidermidis*, greatly improving its efficacy[6]. The results suggest that crude extracts from tested plants damage the cytoplasmic membrane and cause loss of intracellular components. Therefore, the authors propose that observed synergistic effects of plant extracts (essential oils) and oxacillin could be theoretically the results of the perturbation of the cell membrane coupled with the action of oxacillin.

Previously, Torres et al[7] demonstrated antioxidant, antiinflammatory and antimicrobial activities in the ethanolic extract of leaves from *Cuspidaria convoluta* (*C. convoluta*). Regarding antibacterial effect, this extract was active even against methicillin-resistant *Staphylococcus aureus* (*S. aureus*) (MRSA).

The aims of this work were to identify and isolate phenolic compounds from *C. convoluta*, and to evaluate their antibacterial activity and synergistic effects with commercial antibiotics.

2. Materials and methods

2.1. Plant material

The plant was collected in November 2017 in Misiones (Ruta Nacional 12 y Santa Ana, 29° 10'39.274'' S, 58° 51'22.885'' W), Argentina. The plant was identified by specialists from the Herbarium of Instituto de Botánica del Nordeste (IBONE-CONICET), Corrientes, Argentina, where the voucher specimen was deposited (AMG 104).

2.2. Extraction

Leaves were dried at room temperature until constant weight

(10.18% humidity percentage). Then, they were triturated until particle sizes ranged between 1.70 mm and 710 μ m. The crude extract was prepared by maceration (25 g) with methanol (500 mL) for 24 h using a magnetic stirrer at room temperature. The solvent was removed using a rotary evaporator (Buchi, Switzerland). Then, a dark green solid was obtained, most of which was suspended in water and then fractionated successively by *n*-hexane and ethyl acetate. The hexanic, ethyl acetate and water extracts were obtained and evaporated to dryness under vacuum. The extraction yield of each extract was 1.4% for hexanic extract, 3.1% for ethyl acetate extract and 2.5% for water extract. The dried extracts were stored at -20 °C for further use.

2.3. Selection of extract for isolation of bioactive compounds

The most active extract was selected by the determination of its antibacterial activity. The agar overlay bioautography was used according to Nieva Moreno et al[8]. Thin-layer chromatography (TLC) plates (Merck, silica gel 60F254 0.2 thickness) were loaded with a spot containing 60 μ g of each extract (hexanic, ethyl acetate, and water extract). Two strains of *S. aureus* (ATCC 25923 and ATCC 29213) were used, and were provided by the Laboratory of Clinical Analysis of the Hospital Ramón Carrillo, Sáenz Peña, Chaco, Argentina. These strains were maintained in brain heart infusion (Britania Laboratories, Argentina) containing 30% (v/v) glycerol at -20 °C. Plates were incubated for 24 h at 37 °C and then sprayed with thiazolyl blue tetrazolium bromide reagent. Inhibition halos were measured. The extract with higher inhibitory effect was used for the next assays and its total phenol content was determined according to Singleton et al[9]. Besides, the main phenolic compounds of the extract were also analyzed by HPLC-MS/MS. The analysis was performed in negative mode, and the identification of compounds was carried out on the basis of the *m/z* ratio of the quasimolecular ion, fragmentation patterns, data from the literature and/or comparison with patterns. Chromatographic separation was achieved using ACE 3 C18 analytical column (50 mm \times 2.1 mm i.d.; 5 μ m). Mobile phase contained 0.1% of formic acid in water and 0.1% of formic acid in acetonitrile at the flow rate of 0.3 mL/min.

Separation was carried out under the conditions of gradient elution for 30 min. This determination was performed in the Research and Development Center in Chemistry of National Institute of Industrial Technology, Buenos Aires, Argentina.

2.4. Bioguided fractionation of the extract

A portion of the selected extract (10 g) was subjected to column chromatography over silica gel (100-200 mesh). Gradient elution of increasing polarity was initiated with successive elution using hexane (100%), hexane:ethyl acetate (70:30, 50:50 and 30:70), ethyl acetate (100%), ethyl acetate:ethanol (70:30, 50:50 and 30:70), ethanol (100%), ethanol:methanol (70:30, 50:50 and 30:70), and finally only methanol (100%). Fractions having similar TLC profiles were pooled to give the major fraction and were stored in a refrigerator

and evaluated by bioautography. The fractions that showed the presence of halo were subjected to further TLC and bioautographic analysis. The mobile phases used were, phase 1: toluene: ethyl acetate: glacial acetic acid (36:12:5) and phase 2: ethyl acetate: formic acid: glacial acetic acid: water (100:11:11:27). Two plates were performed simultaneously. One plate was sprayed with the polyethylene glycol reagent for natural products (NP/PEG) which was then visualized under visible light and UV at 254 and 365 nm. The second plate was used for the bioautography. At the same time, different phenolic compounds, such as gallic acid, rutin, quercetin, luteolin, and apigenin, were eluted with the different mobile phases for comparison with the separated bands in the TLC. The retention factor (Rf) values of the bands that showed antimicrobial activity were calculated.

2.5. Purification and isolation

Preparative TLC was performed and developed under conditions identical to those described in the previous section. The active bands were identified through TLC profiles by comparison with Rf values and colors of spots from the TLC previously eluted. These bands were scraped off, eluted with methanol and filtered. Subsequently, the solvent (methanol) was evaporated from each of the fractions and a precipitate was obtained which was dissolved in methanol (HPLC grade) and purity analysis was made by HPLC-DAD. The pure compounds were obtained.

2.6. Identification of isolated compounds from fractions

The compounds were tentatively identified by comparison of retention times and their UV-VIS spectra from 200 to 400 nm, as well as by the addition of an external standard. HPLC-MS/MS and IR spectroscopy confirmed the identity of the compounds.

2.7. Determination of antibacterial activity of the isolated compounds

2.7.1. Microorganisms

A total of 12 clinical isolates of ampicillin-resistant *S. aureus*, of which 3 were MRSA and gentamicin resistant (Sa 5307, Sa 5637, and Sa 5722) were used. In addition, Gram-negative bacteria such as *Escherichia coli* (*E. coli*) ATCC 35218, *Pseudomonas aeruginosa* (*P. aeruginosa*) ATCC 27853 and multiresistant clinical isolates of *E. coli* and *P. aeruginosa* were used. These strains were obtained from patients hospitalized at the Hospital Ramón Carrillo, Sáenz Peña, Argentina. Inocula were prepared by adjusting the turbidity of the suspension to match the 0.5 McFarland standards.

2.7.2. Determination of minimum inhibitory concentrations (MICs)

MIC values of the isolated compounds and antibiotic (ampicillin,

gentamicin, and oxacillin) against the tested microorganisms were determined by the broth microdilution method[10]. All compounds were dissolved in dimethyl sulfoxide (DMSO) and two-fold serial dilutions were prepared. The concentration of DMSO used in the assay was 2.9%. Then, 3 μ L of these dilutions and 100 μ L inoculum ($\sim 5 \times 10^5$ CFU/mL) were added to each well. Growth control well contained bacterial cells and 3 μ L of DMSO without any test compound, and sterile control only had growth medium. The concentrations tested for the compounds were 1 600, 800, 400, 200, 100, 50 and 25 μ g/mL. Plates were aerobically incubated at 37 °C for 16-20 h. Bacterial growth was indicated by the presence of turbidity and/or a pellet on the well bottom. The assays were performed in triplicate and as independent tests; and mean values were calculated.

2.7.3. Determination of synergistic activity between natural compounds and commercial antibiotics

The synergy between compounds and selected antibiotics (ampicillin, gentamicin and oxacillin only for MRSA strains) was studied by the checkerboard assay method[11]. With the exception of ATCC strains, all bacteria mentioned in section 2.7.1 were used in this assay. The combinations were transferred to each microplate well. The concentrations used in the combinations for each antibiotic ranged from 0.19 to 1 600 μ g/mL and for each natural compound between 6.25 and 1 600 μ g/mL. MIC values were determined for each antibiotic and for each of these combinations. The bacterial growth and sterile controls were prepared. The fractional inhibitory concentration (FIC) was calculated as follows:

$$FIC_{\text{atb}} = \text{MIC}_{\text{atb}} \text{ in combination with nc} / \text{MIC}_{\text{atb}} \quad (1)$$

$$FIC_{\text{nc}} = \text{MIC}_{\text{nc}} \text{ in combination with atb} / \text{MIC}_{\text{nc}} \quad (2)$$

Where MIC_{atb} is MIC of antibiotics whereas MIC_{nc} MIC of natural compounds.

Then, the FIC Index (FICI) was calculated according to the following equation (3):

$$FICI = FIC_{\text{atb}} + FIC_{\text{nc}} \quad (3)$$

According to Schelz *et al*[12] the FICI values were interpreted as either synergistic (≤ 0.5), additive (>0.5 and ≤ 1), indifferent (>1 and <4) or antagonistic (≥ 4).

For each combination producing synergistic interactions, 6-7 different ratios were tested. All combinations were tested in duplicates in three independent experiments, providing 6 replicates for each combination ratio. Data were presented as the mean of 6 replicates. Data for each ratio examined were plotted on an isobologram, and this was used to determine optimal combination ratios to obtain synergy.

Time-kill assays were only performed against the bacteria most resistant to antibiotics according to Petersen *et al*[13]. Bacterial suspensions with appropriate dilution to $\sim 1 \times 10^5 - 1 \times 10^6$ CFU/mL of each bacterium in broth media were pre-incubated at 37 °C. These samples were co-incubated with natural compounds or antibiotic adjusted to a series of final concentration of $1/2 \times \text{MIC}$, $1 \times \text{MIC}$, and $2 \times \text{MIC}$, with the addition of broth media. Simultaneously, a growth

control without natural compounds/antibiotic was also subjected to this test. In order to count viable cells (CFU), aliquots of 100 μ L were taken from the culture before (0 h, positive control) and after (4, 8, 12 and 24 h) the addition of the drugs using spread plate technique. During the experiment, the mixture was maintained at 37 °C. In addition, the natural compound and the antibiotic, with a series of equal ratio dilution from 1/4×MIC to 1/2×MIC, were combined to explore the combination kill-time according to the same procedure. Three plates were used for each sample. Synergism was demonstrated when there was a reduction of ≥ 2 log CFU/mL of the original inoculum[14].

3. Results

3.1. Identification and isolation of phenolic compounds from *C. convoluta* leaves

3.1.1. Selection of extract for isolation of bioactive compounds

The ethyl acetate extract was the most active extract in the bioautography with inhibition halos larger than 10 mm [(16 \pm 1) mm]. Hexanic extract did not show any activity, while the water extract showed inhibition halos of (12.0 \pm 0.5) mm. The total phenol content of ethyl acetate extract was (32.27 \pm 0.93) mg GAE/g of dry extract. The presence of seven polyphenolic compounds was demonstrated by HPLC-ESI-MS/MS. The phenol compounds identified were coumaric acid derivative, caffeic acid derivative, coumaric acid, catechin/epicatechin, luteolin, hydroxybenzoic acid sugar derivative and cirsiolol.

3.1.2. Bioguided fractionation of the extract

A total of 70 fractions were obtained by column chromatography, of which 6 had antibacterial activity in the bioautographic assay. These fractions demonstrated the presence of more than one compound responsible for the activity. However, only three compounds could

be isolated and purified of these fractions by preparative TLC (Data were not shown).

3.1.3. Purification, isolation and identification of bioactive compounds

Compound 1 (C1) was obtained as compact powder and showed UV absorption at about 345 nm. Its mass spectrum showed a molecular ion and base peak at 165 m/z with other significant peaks at 119. The compound was identified as coumaric acid with the injection of a solution of the pure standards, which matched the feature in both retention time and fragmentation pattern, including an additional fragment at m/z 93.034. The chemical formula of C1 was $C_9H_8O_3$. As *p*-coumaric acid is the most abundant form, the identification was attributed to the *para* isomer. In addition, the IR spectrum exhibited peaks at 3 385 cm^{-1} (carboxylic acid O-H stretching), 1 674 and 1 690 cm^{-1} (carboxylic acid C=O stretching), 1 248 cm^{-1} (carboxylic acid C-O stretching) and 1 510; 1 629 cm^{-1} (aromatic C=C).

Compound 2 (C2) was obtained as amorphous yellow solid. C2 showed a molecular ion peak at m/z 289 and an ion fragment at m/z 245. The presence of this fragment may be caused by a neutral loss of CO_2 . C2 showed a UV spectrum with two maximum of absorption at 239 nm and 280 nm. These features were characteristic of catechins. The enantioseparation of catechin and epicatechin could not be performed so C2 could be catechin or its epimer epicatechin, both with molecular formula $C_{15}H_{14}O_6$. The IR spectrum showed the characteristic absorption regions for O-H group (3 400 – 3 100 cm^{-1}), C = C group around 1 600 cm^{-1} , as well as C – O group (1 150 – 1 010 cm^{-1}).

Compound 3 (C3) was obtained as a yellow needle which showed a molecular ion peak at m/z 285, and fragmentation patterns at 241, 199, 175. In addition, similar to compound 1, a solution of the pure standard luteolin was injected and the retention times and fragmentation patterns were coincident with C3. The molecular

Table 1. MIC values of isolated compounds from *Cuspidaria convoluta* extract and antibiotics on pathogenic bacteria.

Strains	<i>p</i> -Coumaric acid	Catechin/epicatechin	Luteolin	Ampicillin	Gentamicin	Oxacillin
<i>S. aureus</i> ATCC 25923	100	400	100	0.19	0.78	0.39
<i>S. aureus</i> ATCC 29213	100	400	100	0.78	0.78	0.39
<i>S. aureus</i> 5357	100	800	200	3.12	1.56	0.78
<i>S. aureus</i> 5289	100	800	200	6.25	3.12	0.78
<i>S. aureus</i> 5632	50	400	200	6.25	3.12	1.56
<i>S. aureus</i> 5627	400	400	400	3.12	6.25	0.78
<i>S. aureus</i> 5377	100	400	800	6.25	6.25	1.56
<i>S. aureus</i> 5621	200	400	400	1.56	3.12	1.56
<i>S. aureus</i> 5246	100	800	400	3.12	3.12	1.56
<i>S. aureus</i> 5307 [#]	800	800	400	12.50	12.50	25.00
<i>S. aureus</i> 5637 [#]	400	800	400	50.00	50.00	50.00
<i>S. aureus</i> 5722 [#]	400	800	400	50.00	50.00	100.00
<i>E. coli</i> ATCC 35218	800	1 600	400	400.00	400.00	
<i>E. coli</i> [^]	400	1 600	400	400.00	400.00	
<i>P. aeruginosa</i> ATCC 27853	1 600	1 600	800	400.00	400.00	
<i>P. aeruginosa</i> [^]	1 600	1 600	800	800.00	800.00	

Values expressed in μ g/mL. [#] resistant to methicillin and gentamicin, [^]resistant to ampicillin and gentamicin.

Table 2. Interactions of phenolic compounds with ampicillin (A) and gentamicin (G) against pathogenic bacteria.

Strains	A+CA	G+CA	A+C	G+C	A+L	G+L
<i>Sa</i> 5357	0.19/50 ¹ (0.56) ^{2b}	0.39/50 (0.75) ^b	0.78/200 (0.50) ^a	0.78/200 (0.75) ^b	0.19/50 (0.31) ^a	0.39/100 (0.75) ^b
<i>Sa</i> 5289	0.78/50 (0.51) ^b	0.78/50 (0.75) ^b	0.78/200 (0.37) ^a	0.78/200 (0.50) ^a	0.39/50 (0.31) ^a	0.78/50 (0.50) ^a
<i>Sa</i> 5632	0.78/25 (0.51) ^b	1.56/12.5 (0.75) ^b	1.56/200 (0.75) ^b	1.56/200 (1.00) ^b	0.78/50 (0.37) ^a	1.56/50 (0.75) ^b
<i>Sa</i> 5627	0.78/100 (0.50) ^a	0.78/50 (0.25) ^a	0.78/100 (0.50) ^a	0.78/100 (0.37) ^a	0.78/100 (0.50) ^a	0.78/100 (0.37) ^a
<i>Sa</i> 5377	0.39/50 (0.56) ^b	1.56/25 (0.50) ^a	1.56/100 (0.50) ^a	1.56/50 (0.37) ^a	0.78/100 (0.37) ^a	0.78/50 (0.25) ^a
<i>Sa</i> 5621	0.39/50 (0.50) ^a	0.39/50 (0.37) ^a	0.39/100 (0.50) ^a	0.78/100 (0.50) ^a	0.39/100 (0.50) ^a	0.78/100 (0.50) ^a
<i>Sa</i> 5246	0.78/25 (0.50) ^a	0.78/12.5 (0.37) ^a	0.78/200 (0.50) ^a	0.78/100 (0.37) ^a	0.78/100 (0.50) ^a	0.78/50 (0.37) ^a
<i>Sa</i> 5307	3.12/400 (0.75) ^b	0.78/200 (0.31) ^a	3.12/200 (0.50) ^a	3.12/400 (0.75) ^b	3.12/100 (0.50) ^a	3.12/100 (0.50) ^a
<i>Sa</i> 5637	12.5/100 (0.50) ^a	6.25/100 (0.50) ^a	12.5/400 (0.75) ^b	6.25/200 (0.50) ^a	6.25/100 (0.37) ^a	3.12/50 (0.25) ^a
<i>Sa</i> 5722	25/100 (0.50) ^a	12.5/100 (0.50) ^a	25/400 (0.75) ^b	12.5/400 (0.75) ^b	12.5/50 (0.37) ^a	12.5/50 (0.37) ^a
<i>Ec</i>	100/200 (0.75) ^b	100/50 (0.37) ^a	50/400 (0.37) ^a	100/400 (0.50) ^a	12.5/100 (0.28) ^a	100/100 (0.50) ^a
<i>Pa</i>	50/100 (0.09) ^a	400/200 (0.62) ^b	200/200 (0.25) ^a	200/400 (0.50) ^a	12.5/50 (0.08) ^a	200/400 (0.75) ^b

¹MIC values expressed as antibiotic concentration/phenolic compound concentration in the combination (µg/mL) against each bacterial strain. ²FICI values of different combinations between brackets. FICI: Fractional inhibitory concentration index: calculated as mentioned in methods. ^aSynergism (≤ 0.5), ^bAdditivity (> 0.5 and ≤ 1). *Sa*: *S. aureus*; *Ec*: *E. coli*; *Pa*: *P. aeruginosa*. CA: coumaric acid, C: catechin/epicatechin, L: luteolin.




Figure 1. Isobolograms of the combinations of luteolin and ampicillin against resistant bacteria: A) *S. aureus* 5307, B) *S. aureus* 5637, C) *S. aureus* 5722, D) ampicillin resistant *E. coli* and E) ampicillin resistant *P. aeruginosa*.

formula of C3 was $C_{15}H_{10}O_6$, corresponding to luteolin. The IR spectra showed absorption bands for hydroxyl groups (3405 cm^{-1}), aromatic ring (1441 cm^{-1}), carbonyl group (1655 cm^{-1}) and hydroxyl aromatic (1370 cm^{-1}).

3.2. Antibacterial activity of the isolated compounds and their synergistic action with antibiotics

3.2.1. MICs of the isolated compounds

The MIC values of all compounds are shown in Table 1. The results demonstrated that all compounds were active in the bioautographic tests, and exhibited antibacterial activity against all Gram-positive strains in concentrations of 50–800 $\mu\text{g/mL}$, even against MRSA (Sa 5307, 5637, and 5722). Moreover, these phytochemicals had moderate to weak antibacterial activities against different Gram-negative bacteria such as *E. coli* (400–1 600 $\mu\text{g/mL}$), and *P. aeruginosa* (800–1 600 $\mu\text{g/mL}$) strains.

3.2.2. Synergistic activity between natural compounds and commercial antibiotics

With respect to the synergistic effect of these compounds combined with ampicillin and gentamicin, the results are shown in Table 2. In most of these combinations, the FICI exhibited either a synergistic or an additive effect. A strong synergistic interaction was recorded against most of the bacteria with the combination of ampicillin and luteolin (FICI values between 0.08 and 0.50). Isobolograms also confirm the interaction between this antibiotic and luteolin (Figure 1). All graphs showed concave curves, which is characteristic of synergism between compounds ($\text{FICI} \leq 0.5$). The combination of antibiotics with all the tested compounds led to an enhanced antimicrobial effect against *S. aureus* strains even up to 16 times the MIC.

The MIC values of ampicillin and gentamicin were 4–8 times lower when both were used in combination with these phenolic compounds against *E. coli*. Notably, the combination of ampicillin with the three compounds even showed activity against *P. aeruginosa* with a reduction in the MIC of the antibiotic which was between 8–64 times lower.

Based on the time-kill results, all the combinations showed synergism. However, the combination of luteolin with ampicillin was the most relevant. In this case, the synergistic effect against ampicillin-resistant *E. coli* and *P. aeruginosa* strains appeared after 8 h while in the others (coumaric acid and catechin/epicatechin) it appeared only after 12 hours of the trial (data are not shown). Moreover, a bactericidal effect of luteolin/ampicillin was shown at the end of the test (Figure 2). There was sustained synergistic inhibitory activity lasting for more than 24 h; bacterial colony counts were reduced by 2 log CFU/mL when compared with ampicillin alone.

Table 3 and Figure 3 show the synergistic effects of combining these polyphenols with oxacillin for each MRSA strain. This combination decreased the MIC of the antibiotic for each isolate. The MIC of oxacillin decreased by 4–8-fold for MRSA strains. These results demonstrated that the compounds were synergistic with oxacillin for each of the three MRSA strains tested in the plotted isobolograms (Figure 4). Figure 3 shows that the potency of the combined agents was more significant than individual ones; the reduction in colony count was ≥ 2 log CFU/mL over the first 12 hours of trial when the combination of luteolin and oxacillin was used.

Table 3. Interactions of phenolic compounds with oxacillin (O) against MRSA.

Strains	O + coumaric acid	O + catechin/epicatechin	O + luteolin
Sa 5307	6.25/200 ¹ (0.50) ^{2,a}	3.12/200 (0.37) ^a	3.12/100 (0.37) ^a
Sa 5637	12.5/100 (0.50) ^a	12.5/200 (0.50) ^a	6.25/100 (0.37) ^a
Sa 5722	12.5/100 (0.37) ^a	12.5/200 (0.37) ^a	12.5/50 (0.25) ^a

¹MIC values expressed as antibiotic concentration/phenolic compound concentration in the combination ($\mu\text{g/mL}$) against each bacterial strain.

²FICI values of different combinations between brackets. FICI: Fractional inhibitory concentration index: calculated as mentioned in the method part.

^aSynergism (≤ 0.5). MRSA: methicillin-resistant *S. aureus*. Sa: *S. aureus*.




Figure 2. Time kill curves and synergistic effect of luteolin-ampicillin combination against A) ampicillin resistant *E. coli* and B) ampicillin resistant *P. aeruginosa*. Control strain (■), 2 MIC luteolin (◆), 2 MIC ampicillin (■), MIC luteolin (▲), MIC ampicillin (●), 1/2 MIC luteolin (●), 1/2 MIC ampicillin (●), combination 1/2 MIC luteolin and 1/2 MIC ampicillin (◆), combination 1/4 MIC luteolin and 1/4 MIC ampicillin (●).




Figure 3. Time kill curves and synergistic effect of luteolin-oxacillin combination against MRSA strains, A) *S. aureus* 5307, B) *S. aureus* 5637 and C) *S. aureus* 5722. Control strain (■), 2 MIC luteolin (■), 2 MIC oxacillin (■), MIC luteolin (▲), MIC oxacillin (●), ½ MIC luteolin (●), ½ MIC oxacillin (●), combination ½ MIC luteolin and ½ MIC oxacillin (◆), combination ¼ MIC luteolin and ¼ MIC oxacillin (■).




Figure 4. Isobolograms of the combinations of phenolic compounds with oxacillin against MRSA strains. A) coumaric acid-oxacillin against *S. aureus* 5307, B) catechin/epicatechin-oxacillin against *S. aureus* 5307, C) luteolin-oxacillin against *S. aureus* 5307, D) coumaric acid-oxacillin against *S. aureus* 5637, E) catechin/epicatechin-oxacillin against *S. aureus* 5637, F) luteolin-oxacillin against *S. aureus* 5637, G) coumaric acid-oxacillin against *S. aureus* 5722, H) catechin/epicatechin-oxacillin against *S. aureus* 5722 and I) luteolin-oxacillin against *S. aureus* 5722.

4. Discussion

Regarding the phytochemical composition of *C. convoluta*, Torres et al[7] reported the presence of a coumaric acid derivative, luteolin, hydroxybenzoic acid sugar derivative, and cirsiol in its ethanolic extract. In the present work, catechin/epicatechin, luteolin, and *p*-coumaric acid could be isolated and identified. Regarding coumaric acid, its presence has already been reported in other representatives of Bignoniaceae family even in the *Cuspidaria* genus[15,16]. It is also found in *C. convoluta* in this study. Concerning catechins, their presence in the genus *Cuspidaria* has not yet been reported.

In relation to the antimicrobial activity, the results of present study suggest that MIC values close to 100 µg/mL could be considered noteworthy[17]. Therefore, *p*-coumaric acid would be the most active isolated compound with MIC values of 50 and 100 µg/mL against seven *S. aureus* strains. These results are in agreement with those of Lou et al[18] and Orhan et al[19], who reported antimicrobial activity of *p*-coumaric acid against *S. aureus*. However, the MIC value needed to inhibit the growth of MRSA (MIC= 1 000 µg/mL) was higher than that found in this work (MIC= 400-800 µg/mL), and the authors informed that no inhibitory effect was found against methicillin sensible *S. aureus*[20]. On the other hand, MIC values found in this work for *p*-coumaric acid were higher than those reported in other paper for *E. coli* (MIC=80 µg/mL)[18]. This difference is probably due to the different sensitivity of the clinical strains used.

The results of the synergism tests showed that the best combination was ampicillin with luteolin. These were to be expected since, in previous work, the combination of *C. convoluta* extract and ampicillin even showed activity against *P. aeruginosa* (strains Pa and F305) with a reduction in 16 times the MIC of the antibiotic[21]. Several works showed that luteolin increases the efficacy of different antibiotics, since it inhibits β-lactamase in multidrug-resistant *E. coli* strains[22], affects the cytoplasmic membrane stability; and inhibits enzymes involved in the synthesis of folic acid[2]. This could explain the results obtained with the combination of luteolin and ampicillin in this work.

In addition, our results support the findings of Hemaiswarya and Doble[23], who previously demonstrated the ability of *p*-coumaric acid to enhance the effect of commercial antibiotics against Gram-negative and Gram-positive bacteria.

As mentioned above, the phenolic compounds can act synergistically with different classes of antibiotics by several mechanisms[22,24–26]. Concerning the synergistic effect in the luteolin/oxacillin combination against MRSA strains, Joung et al[27] have demonstrated the potential of luteolin as an active therapeutic agent against MRSA, reinforcing the possibility of substantially reducing the use of existing antibiotics.

In conclusion, *p*-coumaric acid, catechin/epicatechin, and luteolin were isolated from *C. convoluta* leaves and identified. Although these

compounds are present in most plants, they have not been isolated from *C. convoluta* and studied yet. This contributes to the knowledge of this species, which until now, has been scarcely studied from the phytochemical perspective.

There is a synergistic interaction between the phenolic compounds isolated from *C. convoluta* and selected antibiotics. The synergy observed allows reducing the dose of antibiotics which translates into a decrease in the adverse effects associated with the use of these drugs. In addition, the mentioned compounds could be a solution for the multidrug resistance problem, but their mechanism of action in different microorganisms should be better understood and further explored, which will allow more effective and safer treatments to be developed than the current ones.

Conflict of interest statement

All authors declare that there is no conflict of interest.

Acknowledgments

We acknowledge the financial support from Secretaría de Ciencia y Técnica UNCAUS and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina. We thank N. E. Cech and C. Fontán from Hospital 4 de Junio from Presidencia Roque Sáenz Peña, Chaco, Argentina for isolation and identification of bacterial strains. We also thank A. M. Gonzalez and M. M. Arbo from IBONE for plant collection and identification.

Funding

This work is financially supported by Secretaría de Ciencia y Técnica UNCAUS and by Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina.

References

- [1] Dudhatra GB, Mody SK, Awale MM, Patel HB, Modi CM, Kumar A, et al. A comprehensive review on pharmacotherapeutics of herbal bioenhancers. *Sci World J* 2012; **2012**: 637953.
- [2] Hemaiswarya S, Kruthiventi AK, Doble M. Synergism between natural products and antibiotics against infectious diseases. *Phytomedicine* 2008; **15**(8): 639-652.
- [3] Wagner H, Ulrich-Merzenich G. Synergy research: Approaching a new generation of phytopharmaceuticals. *Phytomedicine* 2009; **16**(2-3): 97-110.
- [4] Phitaktim S, Chomnawang M, Sirichaiwetchakoon K, Dunkhunthod B,

- Hobbs G, Eumkeb G. Synergism and the mechanism of action of the combination of α -mangostin isolated from *Garcinia mangostana* L. and oxacillin against an oxacillin-resistant *Staphylococcus saprophyticus*. *BMC Microbiol* 2016; **16**(1): 195.
- [5] Siriwong S, Teethaisong Y, Thumanu K, Dunkhunthod B, Eumkeb G. The synergy and mode of action of quercetin plus amoxicillin against amoxicillin-resistant *Staphylococcus epidermidis*. *BMC Pharmacol Toxicol* 2016; **17**: 39.
- [6] Chovanová R, Mikulášová M, Vaverková S. *In vitro* antibacterial and antibiotic resistance modifying effect of bioactive plant extracts on methicillin-resistant *Staphylococcus epidermidis*. *Int J Microbiol* 2013; **2013**: 760969.
- [7] Torres CA, Pérez Zamora CM, Nuñez MB, Gonzalez AM. *In vitro* antioxidant, antilipoxygenase and antimicrobial activities of extracts from seven climbing plants belonging to the Bignoniaceae. *J Integr Med* 2018; **16**(4): 255-262.
- [8] Nieva Moreno MI, Isla MI, Cudmani NG, Vattuone MA, Sampietro AR. Screening of antibacterial activity of Amaicha del Valle (Tucumán, Argentina) propolis. *J Ethnopharmacol* 1999; **68**(1-3): 97-102.
- [9] Singleton VL, Orthofer R, Lamuela-Raventos RM. Analysis of total phenols and other oxidation substrates and antioxidants by means of Folin Ciocalteu reagent. *Meth Enzymol* 1999; **299**: 152-178.
- [10] Clinical and Laboratory Standards Institute (CLSI). Approved Standard 9th Edition M7-A9. *Performance standards for antimicrobial susceptibility test for bacteria that grow aerobically*. USA: Wayne; 2012.
- [11] Moody J. Synergism testing: Broth microdilution checkerboard and broth macrodilution methods. In: Isenberg HD, García Lynne S (eds). *Clinical microbiology procedures handbook*. USA, Washington DC: ASM Press; 2007, p. 1-23.
- [12] Schelz Z, Molnar J, Hohmann J. Antimicrobial and antiplasmid activities of essential oils. *Fitoterapia* 2006; **77**(4): 279-285.
- [13] Petersen PJ, Labthavikul P, Jones CH, Bradford PA. *In vitro* antibacterial activities of tigecycline in combination with other antimicrobial agents determined by checkerboard and time-kill kinetic analysis. *J Antimicrob Chemother* 2006; **57**(3): 573-576.
- [14] Sopirala MM, Mangino JE, Gebreyes Wondwossen A, Biller B, Bannerman T, Balada-Llasat JM, et al. Synergy testing by etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2010; **54**(11): 4678-4683.
- [15] Alvarenga TA, Bêdo TRFO, Braguine CG, Gonçalves UO, Magalhães LG, Rodrigues V, et al. Evaluation of *Cuspidaria pulchra* and its isolated compounds against *Schistosoma mansoni* adult worms. *Int J Biotechnol Wellness Ind* 2012; **1**: 122-127.
- [16] Rahmatullah M, Samarra W, Jahan R, Rahman S, Sharmin N, Ullah Miajee EZUM, et al. An ethnomedicinal, pharmacological and phytochemical review of some Bignoniaceae family plants and a description of Bignoniaceae plants in folk medicinal uses in Bangladesh. *Adv Nat Appl Sci* 2010; **4**(3): 236-253.
- [17] Cushnie TPT, Lamb AJ. Recent advances in understanding the antibacterial properties of flavonoids. *Int J Antimicrob Agents* 2011; **38**(2): 99-107.
- [18] Lou Z, Wang H, Rao S, Sun J, Ma C, Li J. *p*-Coumaric acid kills bacteria through dual damage mechanisms. *Food Control* 2012; **25**(2): 550-554.
- [19] Orhan DD, Özçelik B, Özgen S, Ergun F. Antibacterial, antifungal, and antiviral activities of some flavonoids. *Microbiol Res* 2010; **165**(6): 496-504.
- [20] Alves MJ, Ferreira IC, Froufe HJ, Abreu RM, Martins A, Pintado M. Antimicrobial activity of phenolic compounds identified in wild mushrooms, SAR analysis and docking studies. *J Appl Microbiol* 2013; **115**(2): 346-357.
- [21] Torres CA, Nuñez MB, Isla MI, Castro MP, Gonzalez AM, Zampini IC. Antibacterial synergism of extracts from climbers belonging to Bignoniaceae family and commercial antibiotics against multi-resistant bacteria. *J Herb Med* 2017; **8**: 24-30.
- [22] Eumkeb G, Siriwong S, Thumanu K. Synergistic activity of luteolin and amoxicillin combination against amoxicillin-resistant *Escherichia coli* and mode of action. *J Photochem Photobiol B* 2012; **117**: 247-253.
- [23] Hemaiswarya S, Doble M. Synergistic interaction of phenylpropanoids with antibiotics against bacteria. *J Med Microbiol* 2010; **59**: 1469-1476.
- [24] Amin M, Khurram M, Khattak B, Khan J. Antibiotic additive and synergistic action of rutin, morin and quercetin against methicillin resistant *Staphylococcus aureus*. *BMC Complem Altern Med* 2015; **15**: 59.
- [25] Eumkeb G, Siriwong S, Phitaktim S, Rojtinakorn N, Sakdarat S. Synergistic activity and mode of action of flavonoids isolated from smaller galangal and amoxicillin combinations against amoxicillin-resistant *Escherichia coli*. *J Appl Microbiol* 2011; **112**(1): 55-64.
- [26] Xie Y, Yang W, Tang F, Chen X, Ren L. Antibacterial activities of flavonoids: Structure-activity relationship and mechanism. *Curr Med Chem* 2015; **22**(1): 132-149.
- [27] Joung DK, Kang O, Seo YS, Zhou T, Lee YS, Han SH, et al. Luteolin potentiates the effects of aminoglycoside and β -lactam antibiotics against methicillin resistant *Staphylococcus aureus* *in vitro*. *Exp Ther Med* 2016; **11**(6): 2597-2601.